Akero
Akero is a California-based clinical-stage biotechnology company that research and develops novel medicines for the treatment of non-alcoholic steatohepatitis diseases.
Business Model:
Revenue: $0
Employees: 11-50
Industries / Tags:
Detailed Akero Information
Geographic Data
Address: 601 Gateway Boulevard
City: South San Francisco
State: CA
Zip: 94080
Country: US
Financial Info
Stage:
post ipo debt
Raised Last:
$25M
Raised Total:$260M
Social
Metrics
3,894,120Website Global Rank
3,158Website Monthly Traffic
Twitter Followers
Description
Akero is a California-based clinical-stage biotechnology company that research and develops novel medicines for the treatment of non-alcoholic steatohepatitis diseases.
Contact Phone:
+16504876488
Contact Email:
Akero went public on 6/20/2019 on the NASDAQ
Listed Exchange:
NASDAQ
IPO Date:
6/20/2019
IPO Valuation:
$433M
Ticker Symbol:
AKRO
IPO Price:
$16/share
Amount Raised:
$92M
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 6/2018 | Series A | 4 | $65M |
Apple Tree Partners Atlas Venture venBio Partners Versant Ventures Apple Tree Partners Atlas Venture venBio Partners Versant Ventures |
9/2022 | Post-IPO Equity | $230M | 6/2019 | IPO | $92M |
|
12/2018 | Series B | 12 | $70M |
venBio Partners Cormorant Asset Management BVF Partners LifeSci Venture Partners Janus Henderson Investors Rock Springs Capital Atlas Venture Boxer Capital Janus Henderson Investors Versant Ventures Redmile Group Biotechnology Value Fund venBio Partners Cormorant Asset Management BVF Partners LifeSci Venture Partners Janus Henderson Investors Rock Springs Capital Atlas Venture Boxer Capital Janus Henderson Investors |
6/2022 | Post-IPO Debt | $0 |
Hercules Capital Hercules Capital |
9/2022 | Post-IPO Equity | $200M | 6/2022 | Post-IPO Equity | 1 | $25M |
Pfizer Breakthrough Growth Initiative Pfizer Breakthrough Growth Initiative |
6/2022 | Post-IPO Debt | 1 | $100M |
Hercules Capital Hercules Capital |
|---|
| Announced Date | Name | Price |
|---|
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
